Lung cancer patients who are asymptomatic at diagnosis show favorable prognosis: A Korean Lung Cancer Registry Study

被引:41
作者
In, Kwang-Ho [2 ]
Kwon, Yong-Soo
Oh, In-Jae
Kim, Kyu-Sik
Jung, Maan-Hong [3 ]
Lee, Kwan-Ho [4 ]
Kim, Sun-Young
Ryu, Jeong-Seon [5 ]
Lee, Sung-Yong [2 ]
Jeong, Eun-Taik
Lee, Sang-Yeub [2 ]
Yum, Ho-Kee [6 ]
Lee, Chang-Geol [7 ]
Kim, Woo-Sung [8 ]
Zo, Jae-Ill
Kim, Hojoong [9 ]
Kim, Young-Whan [10 ]
Kim, Se-Kyu [7 ]
Lee, Jae-Cheol [11 ]
Kim, Young-Chul [1 ]
机构
[1] Chonnam Natl Univ, Sch Med, Hwasun Hosp, Lung & Esophageal Canc Clin, Hwasungun 519809, Jeonnam, South Korea
[2] Korea Univ, Seoul, South Korea
[3] Kosin Univ, Pusan, South Korea
[4] Yeungnam Univ, Gyongsan, South Korea
[5] Inha Univ, Inchon, South Korea
[6] Inje Univ, Gimhae, South Korea
[7] Yonsei Univ, Seoul 120749, South Korea
[8] Univ Ulsan, Asan Med Ctr, Ulsan, South Korea
[9] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea
[10] Seoul Natl Univ, Seoul 151, South Korea
[11] Korea Canc Ctr Hosp, Seoul, South Korea
关键词
Lung neoplasms; Registries; Epidemiology; Survival; Korea; SURVIVAL; GEFITINIB;
D O I
10.1016/j.lungcan.2008.08.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose and methods: The outcomes of lung cancer patients who were asymptomatic at diagnosis have never been reported as part of a large-scale study. A national survey of lung cancer in South Korea registered a total of 8788 patients diagnosed in 2005. We report the results herein, with an emphasis on the prognosis of the asymptomatic lung cancer patients. Results: Adenocarcinoma was the most frequent (36.1%) histopathologic type, followed by squamous cell carcinoma (32.1%), large cell carcinoma (1.5%), and small cell carcinoma (13.5%). In most cases, lung cancer was detected with subjective symptoms, but 6.5% of cases had no symptoms indicative of lung cancer at the time of diagnosis. Compared to symptomatic patients, asymptomatic patients were younger, more often female, non-smokers, and more frequently presented with adenocarcinoma. Initial treatments were surgery (22.1%), radiation therapy (7.8%), chemo-radiation therapy (5.4%), and chemotherapy (38%), while 26.6% of patients were recorded to have supportive care only. Asymptomatic patients received surgery in 60.0% of cases, and they showed significantly longer survival times than symptomatic patients. Absence of symptoms at diagnosis significantly reduced the risk of death from non-small cell lung cancer, regardless of patient age, patient gender, stage at diagnosis, smoking history, or whether treatment was performed, but did not reduce the risk of death from small cell lung cancer. Conclusions: Adenocarcinoma has grown to be the leading histopathologic type of lung cancer in South Korea. Absence of symptom at diagnosis is a favorable prognostic factor for patients with non-small cell lung cancer. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:232 / 237
页数:6
相关论文
共 18 条
[1]   A Japanese lung cancer registry study - Prognosis of 13,010 resected lung cancers [J].
Asamura, Hisao ;
Goya, Tomoyuki ;
Koshiishi, Yoshihiko ;
Sohara, Yasunori ;
Eguchi, Kenji ;
Mori, Masaki ;
Nakanishi, Yohichi ;
Tsuchiya, Ryosuke ;
Shimokata, Kaoru ;
Inoue, Hiroshi ;
Nitkiwa, Toshihiro ;
Miyaoka, Etsuo .
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (01) :46-52
[2]   Screening for lung cancer - A review of the current literature [J].
Bach, PB ;
Kelley, MJ ;
Tate, RC ;
McCrory, DC .
CHEST, 2003, 123 (01) :72S-82S
[3]   Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening [J].
Black, WC .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16) :1280-1282
[4]   Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study [J].
Chang, Alex ;
Parikh, Purvish ;
Thongprasert, Sumitra ;
Tan, Eng Huat ;
Perng, Reury- Perng ;
Ganzon, Domingo ;
Yang, Chih-Hsin ;
Tsao, Chao-Jung ;
Watkins, Claire ;
Botwood, Nick ;
Thatcher, Nick .
JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (08) :847-855
[5]  
Henschke CI, 2001, CANCER, V92, P153, DOI 10.1002/1097-0142(20010701)92:1<153::AID-CNCR1303>3.0.CO
[6]  
2-S
[7]  
Henschke CI, 2006, NEW ENGL J MED, V355, P1763, DOI 10.1056/NEJMoa060476
[8]  
International Early Lung Cancer Action Program Investigators, International Early Lung Cancer Action Program protocol
[9]   Predictors of the response to gefitinib in refractory non-small cell lung cancer [J].
Kim, KS ;
Jeong, JY ;
Kim, YC ;
Na, KJ ;
Kim, YH ;
Ahn, SJ ;
Baek, SM ;
Park, CS ;
Park, CM ;
Kim, YI ;
Lim, SC ;
Park, KO .
CLINICAL CANCER RESEARCH, 2005, 11 (06) :2244-2251
[10]  
*KOR NAT STAT OFF, 2007, DEATH RAT STAT KOR 2